Alpha Family Trust Takes Position in Zoetis Inc. (NYSE:ZTS)

Alpha Family Trust acquired a new stake in Zoetis Inc. (NYSE:ZTS) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,090 shares of the company’s stock, valued at approximately $213,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. First Personal Financial Services acquired a new position in Zoetis during the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP acquired a new position in Zoetis during the 3rd quarter worth approximately $33,000. Quarry LP lifted its position in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares in the last quarter. Fortitude Family Office LLC lifted its position in Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after acquiring an additional 222 shares in the last quarter. Finally, LRI Investments LLC acquired a new position in Zoetis during the 1st quarter worth approximately $43,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ZTS. JPMorgan Chase & Co. boosted their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Stifel Nicolaus lifted their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Piper Sandler lifted their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis has an average rating of “Buy” and an average target price of $221.44.

Zoetis Price Performance

Shares of NYSE ZTS opened at $175.14 on Friday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $79.02 billion, a price-to-earnings ratio of 32.92, a price-to-earnings-growth ratio of 2.69 and a beta of 0.90. The business has a 50 day simple moving average of $187.09 and a 200-day simple moving average of $180.23.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the previous year, the business earned $1.36 EPS. The business’s quarterly revenue was up 11.6% on a year-over-year basis. As a group, equities research analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.99%. Zoetis’s payout ratio is currently 32.52%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.